Seal and logotype of Brandeis University The Heller School logo

Recent Conferences

October 12, 2006

Coverage Policy in an Era of Personalized Medicine: Evaluating and Paying for Genetic Testing Services

Personalized Medicine: Business and Regulatory Implications for Health Plans and Pharmaceutical Firms. The emerging field of pharmacogenomics will likely lead to an expansion of therapies targeted to the genetic characteristics of individual patients. This has potentially wide ranging implications for pharmaceutical firms, payers, patients and providers. This meeting examined key policy issues likely to arise from the expansion of personalized therapies for drug firms, payers, and federal regulators.